-
Mashup Score: 0
Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 40
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Transplant without salvage: cut out the middleman - 7 day(s) ago
In this issue of The Lancet Haematology, Matthias Stelljes and colleagues1 present a compelling exploration of an approach to allogeneic haematopoietic stem-cell transplantation (HSCT) in patients at high risk of relapse or induction-refractory acute myeloid leukaemia. This concept is in stark contrast with the long-upheld orthodoxy of using varying regimens of salvage chemotherapy to induce remission or a morphological leukaemia-free state before transplantation.2 These approaches, while considered to be the standard of care in most institutions, are associated with substantial morbidity, particularly when conventional chemotherapy is used.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Findings from SELECT-AML-1 support the potential benefit of tamibarotene in those with acute myeloid leukemia harboring RARA gene overexpression.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML - 13 day(s) ago
Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML - 15 day(s) ago
Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML - 17 day(s) ago
Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML - 20 day(s) ago
Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
Pivekimab sunirine showed single-agent activity across multiple doses, with a recommended phase 2 dose of 0·045 mg/kg once every 3 weeks. These findings led to a phase 1b/2 study of pivekimab sunirine plus azacitidine and venetoclax in patients with CD123-positive acute myeloid leukaemia.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Unpacking the Significance of Liso-Cel’s FDA Approval and Continued Investigation in CLL/SLL - 24 day(s) ago
Saad J. Kenderian, MB, CHB, expands on the significance of liso-cel’s approval in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
“Venetoclax in combination with a hypomethylating agent is currently standard treatment for patients with newly diagnosed AML who are unfit for intensive chemotherapy, including those with mIDH1,” said Jorge E. Cortes, MD. #leusm | @GCC_Cortes https://t.co/JUB8bkClDe